SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Gaarenstroom K. N.)
 

Sökning: WFRF:(Gaarenstroom K. N.) > Clinical Use of Can...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005442naa a2200565 4500
001oai:DiVA.org:uu-275569
003SwePub
008160204s2016 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2755692 URI
0247 a https://doi.org/10.1097/IGC.00000000000005862 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Soletormos, Gyorgyu Univ Copenhagen, North Zealand Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark.4 aut
2451 0a Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer Updated Guidelines From the European Group on Tumor Markers
264 1c 2016
338 a electronic2 rdacarrier
520 a Objective:To present an update of the European Group on Tumor Markers guidelines for serum markers in epithelial varian cancer. Methods: Systematic literature survey from 2008 to 2013. The articles were evaluated by level of evidence and strength of recommendation. Results: Because of its low sensitivity (50-62% for early stage epithelial ovarian cancer) and limited specificity (94-98.5%), cancer antigen (CA) 125 (CA125) is not recommended as a screening test in asymptomatic women. The Risk of Malignancy Index, which includes CA125, transvaginal ultrasound, and menopausal status, is recommended for the differential diagnosis of a pelvic mass. Because human epididymis protein 4 has been reported to have superior specificity to CA125, especially in premenopausal women, it may be considered either alone or as part of the risk of ovarian malignancy algorithm, in the differential diagnosis of pelvic masses, especially in such women. CA125 should be used to monitor response to first-line chemotherapy using the previously published criteria of the Gynecological Cancer Intergroup, that is, at least a 50% reduction of a pretreatment sample of 70 kU/L or greater. The value of CA125 in posttherapy surveillance is less clear. Although a prospective randomized trial concluded that early administration of chemotherapy based on increasing CA125 levels had no effect on survival, European Group on Tumor Markers state that monitoring with CA125 in this situation should occur, especially if the patient is a candidate for secondary cytoreductive surgery. Conclusions: At present, CA125 remains the most important biomarker for epithelial ovarian cancer, excluding tumors of mucinous origin.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reproduktionsmedicin och gynekologi0 (SwePub)302202 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Obstetrics, Gynaecology and Reproductive Medicine0 (SwePub)302202 hsv//eng
653 a Ovarian cancer
653 a CA125
653 a HE4
653 a Screening
653 a Differential diagnosis
653 a Monitoring
7001 a Duffy, Michael J.u St Vincents Univ Hosp, Clin Res Ctr, Dublin 4, Ireland.;Univ Coll Dublin, UCD Sch Med & Med Sci, Conway Inst Bimol & Biomed, Res, Dublin 2, Ireland.4 aut
7001 a Abu Hassan, Suher Othmanu Univ Copenhagen, North Zealand Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark.4 aut
7001 a Verheijen, Rene H. M.u Univ Med, Ctr Utrecht, Dept Gynecol Oncol, Utrecht, Netherlands.4 aut
7001 a Tholander, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)betho227
7001 a Bast, Robert C., Jr.u Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gynecol Med Oncol, Houston, TX 77030 USA.4 aut
7001 a Gaarenstroom, Katja N.u Leiden Univ, Med Ctr, Dept Gynecol, Leiden, Netherlands.4 aut
7001 a Sturgeon, Catharine M.u Royal Infirm Edinburgh NHS Trust, Dept Clin Biochem, Edinburgh, Midlothian, Scotland.4 aut
7001 a Bonfrer, Johannes M.u PUM Netherlands Senior Experts, Senior Expert Clin Labs, Heemstede, Netherlands.4 aut
7001 a Petersen, Per Hyltoftu Univ Bergen, Norwegian Qual Improvement Primary Care Labs NOKL, Sect Gen Practice, Bergen, Norway.4 aut
7001 a Troonen, Hugou Abbott, Limburg, Germany.4 aut
7001 a CarloTorre, Gianu Ctr Ippocrate, Bogliasco, Italy.4 aut
7001 a Kulpa, Jan Kantyu M Sklodowska Curie Mem Inst, Cracow Div, Ctr Oncol, Dept Clin Biochem, Krakow, Poland.4 aut
7001 a Tuxen, Malgorzata K.u Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark.4 aut
7001 a Molina, Raphaelu Hosp Clin Barcelona, Biochem Lab, Barcelona, Spain.4 aut
7102 a Univ Copenhagen, North Zealand Hosp, Dept Clin Biochem, DK-3400 Hillerod, Denmark.b St Vincents Univ Hosp, Clin Res Ctr, Dublin 4, Ireland.;Univ Coll Dublin, UCD Sch Med & Med Sci, Conway Inst Bimol & Biomed, Res, Dublin 2, Ireland.4 org
7730 t International Journal of Gynecological Cancerg 26:1, s. 43-51q 26:1<43-51x 1048-891Xx 1525-1438
8564 u https://doi.org/10.1097/IGC.0000000000000586y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:900469/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-275569
8564 8u https://doi.org/10.1097/IGC.0000000000000586

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy